Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

References

• Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics26, 537–550 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffmann M, Andersson K, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoeconomics Outcomes Res.9, 65–83 (2009).
   PubMedGoogle Scholar
• Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26, 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics27, 1–4 (2009).
   PubMed Web of Science ®Google Scholar
• Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. Appl. Health Econ. Health Policy8(1), 7–24 (2010).
   PubMedGoogle Scholar
• Godman B, Bucsics A, Burkhardt T, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res.8, 357–371 (2008).
   PubMedGoogle Scholar
• Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for healthcare systems? Eurohealth14(2), 18–22 (2008).
   Google Scholar
• Perry G. The European generic pharmaceutical market in review: 2006 and beyond. J. Gen. Med.4, 4–14 (2006).
   Google Scholar
• Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res.9, 569–581 (2009).
   PubMedGoogle Scholar
• Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A. Generic olanzapine: health authority opportunity or nightmare? Expert Rev. Pharmacoeconomics Outcomes Res.8(6), 549–555 (2008).
   PubMedGoogle Scholar
• Duerden M. Making sense of Drug Pricing. Prescriber supplement. John Wiley & Sons Ltd. West Sussex, UK (2006).
   Google Scholar
• Chaplin S, Duerdin M. When Brands are Best: Brand vs. Generic Prescribing: Prescriber Guide. Wiley Interface Ltd, NJ, USA (2006).
   Google Scholar
• Gilley J. Towards rational prescribing. BMJ308, 731–732 (1994).
   PubMed Web of Science ®Google Scholar
• Mason AR, Drummond MF, Hunter JA, Towse AK, Cooke J. Prescribing incentive schemes: a useful approach? Appl. Health Econ. Health Policy4(2), 111–117 (2005).
   PubMedGoogle Scholar
• Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr. Med. Res. Opin.23(1), 105–116 (2007).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care17, 179–189 (2009).
   PubMedGoogle Scholar
• Smith PC and York N. Quality incentives: the case of UK general practitioners. Health Affairs23, 112–118 (2004).
   PubMed Web of Science ®Google Scholar
• Roland M. Linking physicians’ pay to the quality of care – a major experiment in the United Kingdom. N. Eng. J. Med.351, 1448–1454 (2004).
   PubMed Web of Science ®Google Scholar
• Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. N. Engl. J. Med.355, 375–384 (2006).
   PubMed Web of Science ®Google Scholar
• MacBride-Stewart A, Elton R, Walley T. Do quality incentives change prescribing patterns in primary care? An observational study in Scotland. Family Practice25(1), 27–32 (2008).
   PubMed Web of Science ®Google Scholar
• Barrett A, Riques T, Small M et al. How much will Herceptin really cost? BMJ333, 1118–1120 (2006).
   PubMed Web of Science ®Google Scholar
• Delaney B, Ford AC, Forman D et al. Initial management strategies for dyspepsia.Cochrane Database Syst. Rev. (4), CD001961 (2005).
   Google Scholar
• Yang YY, Lewis J, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA296(24), 2947–2953 (2006).
   PubMed Web of Science ®Google Scholar
• Gulmez S, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch. Intern. Med.167, 950–955 (2007).
   PubMed Web of Science ®Google Scholar
• Choudry M, Soran H, Ziglam H. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM101, 445–448 (2008).
   PubMed Web of Science ®Google Scholar
• Leaonard J, Marshall JK, Moavvedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol.102, 2047–2056 (2007).
   PubMed Web of Science ®Google Scholar
• Hawkey C. Drugs that cause and heal peptic ulcer disease. Basic Clin. Pharm. Toxicology105(Suppl. 1), 17 (2009).
   PubMedGoogle Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet371, 117–125 (2008).
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practise: executive summary. Eur. Heart J.28, 2375–2414 (2007).
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial; Heart Protection Study Collaborative Group. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet361, 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J.28, 88–136 (2007).
   PubMed Web of Science ®Google Scholar
• Josan K, Majumdar S, McAlister F. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ178, 576–584 (2008).
   PubMed Web of Science ®Google Scholar
• Walley T, Folino-Gallo P, Schwabe U, van Ganse E; on behalf of the EuroMedStat group. Variations and increase use of statins across Europe: data from administrative databases. BMJ328, 385–386 (2004).
   PubMed Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res.9, 475–484 (2009).
   PubMedGoogle Scholar
• Godman B, Vlahovic-Palcevski, Laius O et al. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. Basic Clin. Pharm. Toxicology105 (Suppl. 1), 37 (2009).
   PubMedGoogle Scholar
• Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy7(3), 1–11 (2009).
   PubMedGoogle Scholar
• Coombes R. GPs saved £400m in 2008 by increasing use of generic drugs. BMJ338, 1230 (2009).
   Google Scholar
• Barton S. Using clinical evidence. BMJ322, 503–504 (2001).
   PubMed Web of Science ®Google Scholar
• Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patient’s care. Lancet362, 1225–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ317, 465–468 (1998).
   PubMed Web of Science ®Google Scholar
• Pillans PI, Kubler PA, Radford JM, Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med. J. Aust.172, 16–18 (2000).
   PubMed Web of Science ®Google Scholar
• Björnsson E, Abrahssom H, Simrén M et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther.24, 945–954 (2006).
   PubMed Web of Science ®Google Scholar
• Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ336, 2–3 (2008).
   PubMed Web of Science ®Google Scholar
• Hjemdahl P, Allhammar A, Heaton C et al. SBU should investigate what is an evidence-based and cost-effective use of statins. Läkartidningen32, 1992–1994 (2009).
   Google Scholar
• Feely J, Bennett K. Epidemiology and economics of statin use. Ir. Med. J.101(6), 188–191 (2008).
   PubMedGoogle Scholar
• Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candersartan in a primary care setting. Int. J. Clin. Pract.61(1), 15–23 (2007).
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract.62, 480–484 (2008).
   PubMed Web of Science ®Google Scholar
• Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int. J. Clin. Pract.63(9), 1320–1326 (2009).
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Vlahovic-Palcevski V et al. Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries. Basic Clin. Pharm. Toxicology105(Suppl. 1), 35 (2009).
   Google Scholar
• Cramer JA, Benedict A, Muszabek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract.62, 76–87 (2008).
   PubMed Web of Science ®Google Scholar
• Kastelein J, Akdim F, Stroes E et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N. Engl. J. Med.358(14), 1431–1443 (2008).
   PubMed Web of Science ®Google Scholar
• Brown GB, Taylor A. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N. Engl. J. Med.358(14), 1504–1507 (2008).
   PubMed Web of Science ®Google Scholar
• Wathen B, Dean T. An evaluation of the impact of NICE guidance on GP prescribing. Br. J. Gen. Pract.54, 103–107 (2004).
   PubMed Web of Science ®Google Scholar